Abstract
In the past twelve years the treatment of all types of syphilis at the University of Chicago Clinics has been planned with the use of much more bismuth than has usually been considered as standard or optimum treatment. In this report we wish to evaluate the results of such treatment of early syphilis, asymptomatic neurosyphilis and tabes dorsalis over a ten year period and compare these results, as far as possible, with corresponding data from the Cooperative Clinical Group studies. PRESENT DAY STATUS OF BISMUTH IN SYPHILOTHERAPY Since Sazerac and Levaditi 1 in 1921 first popularized bismuth as an antisyphilitic drug, it has gone through much the same cycle as was previously traversed by the roentgen ray and arsphenamine and as we have recently seen carried out with sulfanilamide. There was first a period of overoptimism, especially on the part of some members of the French school who hailed bismuth
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
